AREG and cancer: AREG–deficient NK cells exhibit enhanced tumor control across multiple cancer models (Figures 8 and 9), while elevated AREG expression correlates with poor prognosis in diverse malignancies (Figure 9J), establishing NK cell‐derived AREG as a therapeutic target.